- Home
- ASND vs EVR Comparison
ASND vs EVR Comparison
Compare ASND & EVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ASND | EVR |
|---|---|---|
| Founded | 2006 | 1995 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 11.7B |
| IPO Year | 2015 | 2006 |
Fundamental Metrics
Financial Performance| Metric | ASND | EVR |
|---|---|---|
| Price | $212.73 | $320.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 9 |
| Target Price | $256.27 | ★ $320.11 |
| AVG Volume (30 Days) | ★ 571.7K | 362.4K |
| Earning Date | 11-12-2025 | 10-29-2025 |
| Dividend Yield | N/A | ★ 1.05% |
| EPS Growth | N/A | ★ 61.11 |
| EPS | N/A | ★ 12.55 |
| Revenue | $758,592,045.00 | ★ $3,542,875,000.00 |
| Revenue This Year | $104.98 | $24.72 |
| Revenue Next Year | $79.91 | $17.06 |
| P/E Ratio | ★ N/A | $25.50 |
| Revenue Growth | ★ 97.46 | 27.03 |
| 52 Week Low | $118.03 | $148.63 |
| 52 Week High | $223.19 | $364.42 |
Technical Indicators
Market Signals| Indicator | ASND | EVR |
|---|---|---|
| Relative Strength Index (RSI) | 57.24 | 56.13 |
| Support Level | $203.02 | $295.00 |
| Resistance Level | $218.50 | $320.00 |
| Average True Range (ATR) | 10.28 | 11.91 |
| MACD | 0.40 | 2.37 |
| Stochastic Oscillator | 69.31 | 84.98 |
Price Performance
Historical ComparisonAbout ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
About EVR Evercore Inc.
Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. The firm operates globally with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.